文献速递冠心病血脂与心血管预防

二十碳五烯酸乙酯降低冠状动脉旁路移植术后患者缺血事件:REDUCE-IT CABG分析

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
PubMed 文献 · Circulation · 2021-10-28

REDUCE-IT为多中心安慰剂对照双盲试验,纳入他汀治疗下低密度脂蛋白胆固醇控制良好且轻中度高甘油三酯血症患者,随机接受二十碳五烯酸乙酯4 g/日或安慰剂。本分析针对有冠状动脉旁路移植术史亚组,结果显示二十碳五烯酸乙酯显著降低主要终点、关键次要终点及总缺血事件。

要点

  • CABG术后患者使用二十碳五烯酸乙酯显著降低主要终点(HR 0.76)和关键次要终点(HR 0.69)。
  • 绝对风险降低6.2%,中位随访4.8年需治疗人数为16。
  • 安全性总体与全研究相似,但需关注心房颤动/扑动住院率升高。

核心结论

  • 在有冠状动脉旁路移植术史的患者中,二十碳五烯酸乙酯治疗与首次及复发缺血事件显著减少相关。

研究设计与样本

  • REDUCE-IT为多中心、安慰剂对照、双盲试验,共随机8179例他汀治疗下低密度脂蛋白胆固醇控制良好且轻中度高甘油三酯血症患者。
  • 本分析为其中1837例(22.5%)有冠状动脉旁路移植术史患者的亚组分析,897例随机至二十碳五烯酸乙酯组,940例至安慰剂组。

主要发现

  • 二十碳五烯酸乙酯组主要终点风险显著降低(HR 0.76,95%CI 0.63-0.92,P=0.004)。
  • 关键次要终点风险显著降低(HR 0.69,95%CI 0.56-0.87,P=0.001)。
  • 总(首次加后续或复发)缺血事件率比显著降低(率比0.64,95%CI 0.50-0.81,P=0.0002)。
  • 首次事件绝对风险降低6.2%(95%CI 2.3%-10.2%),中位随访4.8年需治疗人数为16(95%CI 10-44)。
  • 安全性总体与全研究相似,但需住院至少24小时的心房颤动/扑动发生率升高(5.0% vs 3.1%,P=0.03),出血增加无统计学意义。

临床怎么用

  • 对于有冠状动脉旁路移植术史且他汀治疗下低密度脂蛋白胆固醇控制良好、伴轻中度高甘油三酯血症的患者,可考虑加用二十碳五烯酸乙酯4 g/日以降低缺血事件风险。
  • 治疗决策时应权衡缺血事件减少的获益与心房颤动/扑动住院风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in surgery and pharmacotherapy, there remains significant residual ischemic risk after coronary artery bypass grafting surgery. METHODS: In REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial), a multicenter, placebo-controlled, double-blind trial, statin-treated patients with controlled low-density lipoprotein cholesterol and mild to moderate hypertriglyceridemia were randomized to 4 g daily of icosapent ethyl or placebo. They experienced a 25% reduction in risk of a primary efficacy end point (composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina) and a 26% reduction in risk of a key secondary efficacy end point (composite of cardiovascular death, myocardial infarction, or stroke) when compared with placebo. The current analysis reports on the subgroup of patients from the trial with a history of coronary artery bypass grafting. RESULTS: Of the 8179 patients randomized in REDUCE-IT, a total of 1837 (22.5%) had a history of coronary artery bypass grafting, with 897 patients randomized to icosapent ethyl and 940 to placebo. Baseline characteristics were similar between treatment groups. Randomization to icosapent ethyl was associated with a significant reduction in the primary end point (hazard ratio [HR], 0.76 [95% CI, 0.63-0.92]; P=0.004), in the key secondary end point (HR, 0.69 [95% CI, 0.56-0.87]; P=0.001), and in total (first plus subsequent or recurrent) ischemic events (rate ratio, 0.64 [95% CI, 0.50-0.81]; P=0.0002) compared with placebo. This yielded an absolute risk reduction of 6.2% (95% CI, 2.3%-10.2%) in first events, with a number needed to treat of 16 (95% CI, 10-44) during a median follow-up time of 4.8 years. Safety findings were similar to the overall study: beyond an increased rate of atrial fibrillation/flutter requiring hospitalization for at least 24 hours (5.0% vs 3.1%; P=0.03) and a nonsignificant increase in bleeding, occurrences of adverse events were comparable between groups. CONCLUSIONS: In REDUCE-IT patients with a history of coronary artery bypass grafting, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01492361.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Verma S, Bhatt DL, Steg PG, et al. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation. 2021. PMID: 34710343. doi:10.1161/CIRCULATIONAHA.121.056290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。